Lege Artis Medicinae

[The future of chest X-ray screening in Hungary]

AJKAY Zoltán

JULY 20, 2002

Lege Artis Medicinae - 2002;12(06-07)

[In 2001 4.095.134 chest screening examinations were carried out at 154 fixed and 50 mobile Xray screening stations in Hungary. Currently, screening for tuberculosis is mandatory by law, but a recently issued decree by the Health Minister states that the method is suitable for the screening of lung cancer as well. Unfortunately, the majority of the machines are old and since replacements are long overdue, the assessment with a high technical standard and quality is not always possible. These are the reasons why a plan must be outlined for the necessary improvement and for the renewal of the equipment pool, based on expert opinion. In the literature, there are ongoing spirited discussions on the efficacy of X-ray screening as well as on the possibilities of CT-scans for the identification of lung cancer. The size of the investment needed makes it necessary that costbenefit factors and the possibility of joining the National Health Prevention program should be considered.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Annual Meeting of the Hungarian Association of Gastroenterologists]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[16th Congress of the Hungarian Association for Diabetology]

BREYER Helga, MADARÁSZ Eszter

Lege Artis Medicinae

[Changes in the treatment of childhood asthma with inhalational steroids]

CSERHÁTI Endre

[Since about 30 years, inhalational steroids are the most important drugs in the treatment of persistent (chronic) asthma. According to the severity of the disease, small, medium and high doses of steroids should be given, often together with long lasting beta-agonists. In the last years the therapeutical advice was simplified as the cromolyns and the theophyllins were almost excluded. Leukotrien antagonists appeared either in combination or as monotherapy. Using conventional doses in inhalational steroid therapy there are hardly any side effects, but it is important to give the smallest possible effective dose while achieving maximum bioavailability. Patients all over the world - including Hungary - do not receive optimal antiasthmatic therapy or use drugs ideally, which is especially true to inhalational steroids, resulting in a treatment much less efficient than possible.]

Lege Artis Medicinae

[Functional genomics - Potentials, hopes, and post genomic realism]

FALUS ANDRÁS, SZALAI Csaba, TÓTH Sára

[This paper provides an overview on major elements of the age of genomics: including the human genome programme, principles of gene chip technology and data management by bioinformatics. The manuscript provides examples from the fields of oncology, infectology and allergy. The possibility of ”in silico” research on computers is also presented with the shadows of the post-genomic era and the significance of changes in the biomedical paradigm.]

Lege Artis Medicinae

[Report on the gastroenterological endoscopic activity in Hungary, 2001]

NAGY György, JUHÁSZ László

All articles in the issue

Related contents

Lege Artis Medicinae

[Modern surgical treatment of lung cancer]

AGÓCS László

[Lung cancer is one of the most malignant human cancers because of its high incidence and high mortality rate. The 5-year relative survival rate for lung cancer at the initial diagnosis is 5-15%. Stage I or stage II non-small cell lung cancer (NSCLC) are considered early stage disease. Unfortunately, these two stages combined account for only 25 to 30% of tumours at the initial detection. At present, surgical resection remains the recommended treatment for patients with stage I and II NSCLC. Despite negative preoperative staging studies including mediastinoscopy, as many as one fourth of the patients will be found at surgery to have an occult N2 or one nodal station positive metastatic – stage IIIA – disease. Multimodality therapy is preferred for all subsets of stage IIIA patients. In stage IIIB and IV, surgical resection is possible and indicated only in selected cases, including Pancoast tumours, T4N0,1M0 tumours, the presence of satellite nodules in the same lobe, and certain solitary metastases. Patients with clinical stage T1-2 N0 small cell lung cancer (SCLC) may benefit from surgery for confirmation of diagnosis and improved local control when combined with chemotherapy. The mortality and morbidity rates of surgery in the treatment of lung cancer are reasonably low.]

Lege Artis Medicinae

[Five nine year results of „Comprehensive Health Screening of Hungary 2010-2020-2030”]

BARNA István, DAIKI Tenno, KÉKES Ede, DANKOVICS Gergely

[2010 a new, complex screening program started in Hungary, named Nationwide Comprehensive Health Protection Screening Program in Hungary 2010-2020-2030. The screening was installed on a specially furnished lorry, which is able and will be able to get anywhere from big cities to the smallest villages. The Program as part of the “Heart and Vascular National Program” works with the support of 74 professional-scientific societies and companies. The screening program took place in a specially furnished lorry. The lorry has an easy access to the disabled, operation was performed with the quality control and permission of ÁNTSZ. Near the lorry there were activities for the preservation of health and prevention of illnesses. Within the framework of the Program in the largest mobile diagnostics center in Hungary 37 comprehensive surveys in free form. This enormous special screening station allows 5,100 tests to be performed at each of the 200 screening stations nationwide. The screening program for over 20 years provides 15 million trials on 3,000 scenes and 1 million adult visitors in free humanitarian. The European National Health Program and the National Program for the Prevention and Treatment of Car­dio­vascular Diseases co-ordinated by the Asso­ciation of Hungarian Medical Asso­ciations (MOTESZ) are implemented by con­sensual cooperation. Based on the results, it was re-confirmed that Hungarian population belonged to the high risk group in several aspects. Authors also outlined solution plans for general risk reduction and disease prevention. ]

Clinical Oncology

[Treatments of brain tumors in adults – an up-date]

BAGÓ Attila György

[The prognosis of brain metastases is very poor. Surgery and radiotherapy provides the fi rst line treatment, while systemic therapy has limited value. Nevertheless, our knowledge is increasing: normal cells contribute signifi cantly to the homing and growth of tumor cells; the molecular profi le of the primary tumor and its metastases could be different, which infl uences the therapeutic strategies; the type of blood supply can change during the tumor growth. It would be very important to optimize the cooperation of the different therapeutic modalities, and to fi nd markers which could predict the risk of metastatization.]

Lege Artis Medicinae

[The realization of public health strategies and health-screening in the light of the results of the “comprehensive health screening of Hungary 2010-2017” program]

KISS István, BARNA István, DAIKI Tenno, DANKOVICS Gergely, KÉKES Ede

[The European Healthcare Consumer Index (EHCI) 2017 of Hungary is critically low. Hungarian’s EHCI evaulation are particularly bad in obesity, in nutrition and in physical activity. The ”Comprehensive Health Screening of Hungary 2010-2020" (MÁESZ), has been designed for 10 years, and the first eight years can be considered succesfull. In 2017, 23 931 people participated in a comprehensive screening test, which results 183 655 individuals over the eight years. In this paper, the authors summarize the main achievements of 2017 of MÁESZ. The eight years of the program has been demonstrating the lack of health-conscious behavior, and the deficiencies of health care in Hungary. ]

Clinical Oncology

[Immunotherapy of lungcancer – an update]

OSTOROS Gyula

[Ten years ago the median survival of small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC) was less than one year. In the case of SCLC the situation did not change. There are revolutionary new possibilities in the treatment of NSCLC (histology based cytotoxic chemotherapy, molecular targeted therapy etc.). Unfortunately there is no signifi cant development in treatment strategy of SCLC in the last 30 years. Nowadays in NSCLC immune check point inhibitor therapy is a novel treatment method in the clinical praxis as well. The integration of the PD axis and the CTLA4 inhibitors in the complex therapy of the management of NSCLC is a new challenge. The pembrolizumab monotherapy in fi rst line setting is a new standard of care with high PDL1 expression. In second line setting the pembrolizumab, nivolumab and atezolizumab widely used in clinical praxis as well. In locally advanced disease of NSCLC after radiochemotherapy the durvalumab maintenance monotherapy showed a signifi cant progression free survival benefi t, comparing to placebo. We have got new treatment possibilities in the treatment of SCLC as well. The results of clinical trials with antibody conjugate therapy are promising. The nivolumab monotherapy and the combination treatment of nivolumab + ipilimumab gave promising results as well. In the treatment of SCLC and NSCLC there is a need for biomarker selected therapy (tumor mutational burden [TMB], DLL3, cMyc etc.). Based on the new positive results of the clinical trials there is a possibility to transform lung cancer from a subacute disease to a chronic illness.]